This HTML5 document contains 102 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/drugbank/company/
n15http://linked.opendata.cz/resource/drugbank/drug/DB03904/identifier/pharmgkb/
n22http://linked.opendata.cz/resource/drugbank/dosage/
n12http://linked.opendata.cz/resource/drugbank/drug/DB03904/identifier/kegg-compound/
n10http://linked.opendata.cz/resource/drugbank/drug/DB03904/identifier/pdb/
n13http://linked.opendata.cz/resource/drugbank/drug/DB03904/identifier/bindingdb/
n7http://linked.opendata.cz/resource/drugbank/drug/DB03904/identifier/pubchem-compound/
n23http://bio2rdf.org/drugbank:
n8http://linked.opendata.cz/resource/drugbank/drug/DB03904/identifier/pubchem-substance/
n20http://www.drugs.com/cons/
n9http://linked.opendata.cz/resource/drugbank/drug/DB03904/identifier/kegg-drug/
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB03904/identifier/drugbank/
n18http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n16http://linked.opendata.cz/resource/drugbank/drug/DB03904/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/drugbank/drug/DB03904/identifier/chebi/

Statements

Subject Item
n2:DB03904
rdf:type
n3:Drug
n3:description
A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. [PubChem]
n3:dosage
n22:271B4E2E-363D-11E5-9242-09173F13E4C5 n22:271B4E2F-363D-11E5-9242-09173F13E4C5
n3:group
experimental
n3:indication
<ul> <li>10% hydrate skin</li> <li>15% accelerate fibrin degradation</li> <li>20-30% are antipruritic, break down keratin, decrease the thickness of the stratum corneum and are used in scaling conditions such as ichthysosis</li> <li>40% are proteolytic and may be used to dissolve and peel dystrophic nails</li> </ul> <br>[Patient Self Care, 2010]</br>
owl:sameAs
n18:DB03904 n23:DB03904
dcterms:title
Urea
adms:identifier
n7:1176 n8:46508687 n9:D00023 n10:URE n11:DB03904 n12:C00086 n13:24961 n14:16199 n15:PA451831 n16:42536-6044
n3:packager
n5:271B4E10-363D-11E5-9242-09173F13E4C5 n5:271B4E11-363D-11E5-9242-09173F13E4C5 n5:271B4E0F-363D-11E5-9242-09173F13E4C5 n5:271B4E12-363D-11E5-9242-09173F13E4C5 n5:271B4E13-363D-11E5-9242-09173F13E4C5 n5:271B4E2D-363D-11E5-9242-09173F13E4C5 n5:271B4E2B-363D-11E5-9242-09173F13E4C5 n5:271B4E2C-363D-11E5-9242-09173F13E4C5 n5:271B4E19-363D-11E5-9242-09173F13E4C5 n5:271B4E1A-363D-11E5-9242-09173F13E4C5 n5:271B4E1D-363D-11E5-9242-09173F13E4C5 n5:271B4E1E-363D-11E5-9242-09173F13E4C5 n5:271B4E1B-363D-11E5-9242-09173F13E4C5 n5:271B4E1C-363D-11E5-9242-09173F13E4C5 n5:271B4E21-363D-11E5-9242-09173F13E4C5 n5:271B4E22-363D-11E5-9242-09173F13E4C5 n5:271B4E1F-363D-11E5-9242-09173F13E4C5 n5:271B4E20-363D-11E5-9242-09173F13E4C5 n5:271B4E25-363D-11E5-9242-09173F13E4C5 n5:271B4E26-363D-11E5-9242-09173F13E4C5 n5:271B4E23-363D-11E5-9242-09173F13E4C5 n5:271B4E24-363D-11E5-9242-09173F13E4C5 n5:271B4E27-363D-11E5-9242-09173F13E4C5 n5:271B4E15-363D-11E5-9242-09173F13E4C5 n5:271B4E29-363D-11E5-9242-09173F13E4C5 n5:271B4E2A-363D-11E5-9242-09173F13E4C5 n5:271B4DFE-363D-11E5-9242-09173F13E4C5 n5:271B4E28-363D-11E5-9242-09173F13E4C5 n5:271B4DFF-363D-11E5-9242-09173F13E4C5 n5:271B4E02-363D-11E5-9242-09173F13E4C5 n5:271B4E03-363D-11E5-9242-09173F13E4C5 n5:271B4E00-363D-11E5-9242-09173F13E4C5 n5:271B4E01-363D-11E5-9242-09173F13E4C5 n5:271B4E06-363D-11E5-9242-09173F13E4C5 n5:271B4E07-363D-11E5-9242-09173F13E4C5 n5:271B4E04-363D-11E5-9242-09173F13E4C5 n5:271B4E05-363D-11E5-9242-09173F13E4C5 n5:271B4E0A-363D-11E5-9242-09173F13E4C5 n5:271B4E0B-363D-11E5-9242-09173F13E4C5 n5:271B4E08-363D-11E5-9242-09173F13E4C5 n5:271B4E09-363D-11E5-9242-09173F13E4C5 n5:271B4E0E-363D-11E5-9242-09173F13E4C5 n5:271B4E14-363D-11E5-9242-09173F13E4C5 n5:271B4E0C-363D-11E5-9242-09173F13E4C5 n5:271B4E0D-363D-11E5-9242-09173F13E4C5 n5:271B4E18-363D-11E5-9242-09173F13E4C5 n5:271B4E16-363D-11E5-9242-09173F13E4C5 n5:271B4E17-363D-11E5-9242-09173F13E4C5
n3:synthesisReference
Ryo Yoshida, Haruhiko Katoh, Seizo Sumida, Ichiki Takemoto, Junya Takahashi, Katsuzo Kamoshita, "Urea derivatives, and their production and use." U.S. Patent US4334912, issued 0000.
foaf:page
n20:urea-intravenous.html
n3:IUPAC-Name
n4:271B4E34-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4E3A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4E39-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4E36-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4E37-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4E38-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4E32-363D-11E5-9242-09173F13E4C5 n4:271B4E4A-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4E30-363D-11E5-9242-09173F13E4C5 n4:271B4E33-363D-11E5-9242-09173F13E4C5 n4:271B4E4C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4E31-363D-11E5-9242-09173F13E4C5 n4:271B4E4D-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B4E4F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4E40-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4E41-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4E3B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4E3C-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4E3E-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4E3D-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4E3F-363D-11E5-9242-09173F13E4C5
n3:caco2-Permeability
n4:271B4E4E-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
57-13-6
n3:Bioavailability
n4:271B4E46-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4E48-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4E49-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4E4B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4E45-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4E44-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4E47-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4E35-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4E42-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4E43-363D-11E5-9242-09173F13E4C5